• "Fireworks After All in Disneyland: ASCO 2009 . . . was expected to be a low-key meeting with little exciting data. However . . . we believe it could be remembered as a landmark conference for molecularly targeted therapy. In our opinion, patient selection and drug development for an enriched population emerged as a key theme."

-Howard Liang, Leerink Swann, research note 06/02/09

• "While BIIB's ongoing proxy battle makes for good theater, we would continue to point out that no matter who sits on the board, this company faces numerous commercial challenges."

-Chris Raymond, Robert W. Baird & Co., research note 06/03/09

• "ANDS Punts Partnership: In a disappointing announcement . . . Anadys conceded defeat on partnering ANA-598. . . . We believe [the] rash issue raised sufficient concern to scuttle any partnership at this point. . . . With positive data, Anadys may be able to bring suitors back to the table for a potential partnership next year."

-Edward Tenthoff, Piper Jaffray & Co., research note 06/04/09

• "In the wake of last week's JNJ deal to buy cancer biotech CGRB, takeover premiums . . . are rising; the benefit of a powerful three-month rally has improved some investors' attitudes toward risk in general and public biotechs in particular."

-John Sullivan, Leerink Swann, research note 06/01/09